Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Kingsoft Cloud to Report First Quarter 2024 Financial Results on May 22, 2024
-
Boussard & Gavaudan Investment Management LLP: Form 8.3 - Network International Holdings PLC
-
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Wood Group (John) plc
-
Man Group PLC : Form 8.3 - Barratt Developments plc
-
Man Group PLC : Form 8.3 - Tyman plc
-
Standard Lithium Reports Fiscal Third Quarter 2024 Results, Schedules Investor Update Call
-
Nevada Copper Files Financial Statements and MD&A for the Quarter Ended March 31, 2024
-
Xometry Reports First Quarter 2024 Results
-
Nevada Copper Files Financial Statements and MD&A for the Quarter Ended March 31, 2024
-
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
-
Allegro MicroSystems Reports Fourth Quarter and Fiscal Year 2024 Results
-
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
-
Tower Semiconductor Reports 2024 First Quarter Financial Results
-
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
-
Treasury Metals and Blackwolf Announce Upsize to Concurrent Financing
-
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
-
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Optinose Announces $55 Million Registered Direct Offering
-
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
-
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
-
Cerence Announces Second Quarter Fiscal Year 2024 Results
-
Lantronix to Participate in the 19th Annual Needham Technology, Media, & Consumer Investor Conference on May 14, 2024
-
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
-
The Tile Shop Reports First Quarter 2024 Results
-
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
-
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
-
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
-
BigCommerce Announces First Quarter 2024 Financial Results
-
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
-
Lifetime Brands, Inc. Reports First Quarter 2024 Financial Results
-
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
-
Royalty Pharma Reports First Quarter 2024 Results
-
Advantage Solutions Reports First Quarter Results with New Reporting Segments and Reaffirms its 2024 Outlook
-
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
PhotonPay and Discover® Global Network Connect to Launch PhotonPay Commercial Card
-
Tecnoglass Reports First Quarter 2024 Results
-
Aduro Clean Technologies Selected to Present at Chemelot Circular Hub Event in the Netherlands
-
Sterling Reports First Quarter 2024 Results
-
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
-
Dragonfly Energy Announces Breakthrough in Lithium Battery Production: Eliminating Harmful “Forever Chemicals”
-
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
-
Plug Announces First Quarter 2024 Financial Results
-
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
-
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
-
LanzaTech Announces First Quarter 2024 Financial Results and Reiterates Full Year 2024 Outlook
-
Applied Therapeutics Reports First Quarter 2024 Financial Results
-
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors


